PTC Therapeutics Inc (PTCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PTC Therapeutics Inc (PTCT) has a cash flow conversion efficiency ratio of 0.327x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.04 Million) by net assets ($-180.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is PTC Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
PTC Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how PTC Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of PTC Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
PTC Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PTC Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VSE Corporation
NASDAQ:VSEC
|
0.024x |
|
UL Solutions Inc.
NYSE:ULS
|
0.164x |
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
0.022x |
|
Starwood Property Trust Inc
NYSE:STWD
|
0.045x |
|
Brookfield Business Corp
NYSE:BBUC
|
0.049x |
|
Elis SA
PA:ELIS
|
0.226x |
|
Zillow Group Inc Class C
NASDAQ:Z
|
0.045x |
|
Ternium SA DRC
BA:TXR
|
0.013x |
Annual Cash Flow Conversion Efficiency for PTC Therapeutics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of PTC Therapeutics Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of PTC Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-205.31 Million | $711.20 Million | -3.464x | -3632.12% |
| 2024-12-31 | $-1.10 Billion | $-107.69 Million | 0.098x | -49.33% |
| 2023-12-31 | $-818.55 Million | $-158.42 Million | 0.194x | -81.17% |
| 2022-12-31 | $-347.09 Million | $-356.65 Million | 1.028x | +100.59% |
| 2021-12-31 | $1.44 Million | $-251.33 Million | -174.779x | -43306.93% |
| 2020-12-31 | $481.98 Million | $-194.07 Million | -0.403x | -142.61% |
| 2019-12-31 | $594.33 Million | $-98.64 Million | -0.166x | -110.59% |
| 2018-12-31 | $350.73 Million | $-27.64 Million | -0.079x | -22.52% |
| 2017-12-31 | $156.44 Million | $-10.06 Million | -0.064x | +92.57% |
| 2016-12-31 | $119.58 Million | $-103.57 Million | -0.866x | -107.89% |
| 2015-12-31 | $298.47 Million | $-124.34 Million | -0.417x | -117.09% |
| 2014-12-31 | $298.47 Million | $-57.27 Million | -0.192x | +44.16% |
| 2013-12-31 | $136.54 Million | $-46.92 Million | -0.344x | -113.76% |
| 2012-12-31 | $-19.19 Million | $-47.93 Million | 2.497x | +2768.93% |
| 2011-12-31 | $-238.60 Million | $-20.77 Million | 0.087x | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more